This company has been acquired
TYME Stock Overview
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Tyme Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.31 |
| 52 Week High | US$1.14 |
| 52 Week Low | US$0.22 |
| Beta | 0.92 |
| 1 Month Change | -6.70% |
| 3 Month Change | 15.07% |
| 1 Year Change | -69.84% |
| 3 Year Change | -82.04% |
| 5 Year Change | -94.16% |
| Change since IPO | -94.08% |
Recent News & Updates
Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger
Sep 15We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth
Aug 05
Recent updates
Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger
Sep 15We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth
Aug 05TYME stock surges on merger agreement and Syros Pharmaceuticals
Jul 05Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives
May 26We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth
Mar 19Tyme Technologies Offers Incredible Risk-Reward
Dec 07Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation
Nov 19Tyme Technologies: The Market Missed The Bullish Memo
Aug 27We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate
Jul 19Tyme Technologies reports FY results
Jun 10Tyme Technologies: Recent Sell-Off Provides Opportunity To Buy At A Discount
May 29Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation
Mar 26Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?
Feb 19
Tyme falls after equity offer as quarterly data indicate liquidity pressure
Feb 04Tyme stock granted U.S. patent claims for using TYME-19 to treat COVID-19 infections
Feb 03Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?
Feb 02Revisiting Tyme Technologies
Dec 17Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?
Dec 16Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?
Dec 09Tyme Technologies names new finance chief
Nov 30Shareholder Returns
| TYME | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 26.9% | 1.5% | 1.2% |
| 1Y | -69.8% | 1.1% | 24.7% |
Return vs Industry: TYME underperformed the US Biotechs industry which returned -28% over the past year.
Return vs Market: TYME underperformed the US Market which returned -18.6% over the past year.
Price Volatility
| TYME volatility | |
|---|---|
| TYME Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TYME has not had significant price volatility in the past 3 months.
Volatility Over Time: TYME's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 13 | Richie Cunningham | www.tymeinc.com |
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors.
Tyme Technologies, Inc. Fundamentals Summary
| TYME fundamental statistics | |
|---|---|
| Market cap | US$53.50m |
| Earnings (TTM) | -US$24.19m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.2x
P/E RatioIs TYME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TYME income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$24.19m |
| Earnings | -US$24.19m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TYME perform over the long term?
See historical performance and comparison